Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity

Recruiting

• Conditions: Nervous System Disease; Immune System Disease

• Registration Number: NCT06169150
• Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary

Background:

Immune system and nervous system have significant interaction so that People with immunity diseases can have complications that affect the nervous system and people with some neurological disease may have defects in their immune system.These complications can affect many body functions, including how they move, walk, think, and feel. Researchers do not fully understand how immune diseases affect the nervous system. By learning more, they hope to create more effective treatments.

Objective:

To learn more about the interaction between immune and nervous system and how immunity disease affect the nervous system.

Eligibility:

People aged 2 years and older with an immunity disease. Their healthy biological relatives and other healthy volunteers are also needed.

Design:

Participants will be screened. Blood will be drawn for research. They may have imaging scans. Adults may undergo lumbar puncture: A needle will be inserted into their back to collect fluid from the space around the spinal cord. The imaging scans and lumbar puncture will be optional for healthy relatives and volunteers.

All participants will have 1 study visit per year for 5 years.

They will be asked to donate samples of body fluids at each visit. Blood samples are required for the study. All other donations are optional. These may include saliva, urine, breast milk, stool, vaginal secretions, and wound drainage.

Affected participants may be asked for a skin biopsy: A small sample of skin will be removed. They may also be photographed or videotaped to record the symptoms of their disease.

Tests for each study visit may be spread over several days, if needed.

Visits may be at the clinic. Participants may also collect their own samples at home and send them to the researchers....

Detailed Description

Study Description:

In this study, we will characterize clinical neurologic presentations of patients with known or unevaluated primary and acquired errors of immunity. Investigating the underlying mechanisms of neurologic diseases and their genetic and immunologic bases requires periodic clinical evaluation of these patients and research analyses of their biospecimens. These biospecimens include blood, cerebrospinal fluid (CSF), urine, saliva, skin, breast milk, stool, vaginal specimens, and wound drainage. Magnetic resonance imaging (MRI) of the neural axis may also be done. Data and excess biospecimens from routine clinical care may also be collected and used for research. We propose to evaluate patients who either have or are suspected of having immune defects or other types of host defense defects with neurologic presentations. Unaffected biological relatives and healthy volunteers will also be enrolled as controls for research analyses.

Primary Objectives:

1. Clinically characterize neurologic manifestations of errors of immunity via neurologic exam and neuroimaging.

2. Determine genetic defects in participants.

Secondary Objective:

Characterize immune cells in CSF and blood.

Primary Endpoints:

1. Clinical characterization of neurologic manifestations in participants with recognized and unrecognized errors of immunity based on neurologic examination, neuroimaging, and other necessary neurologic tests depending on clinical presentation.

2. Characterization of inherited or acquired errors of immunity in participants with rare neurologic diseases.

Secondary Endpoint:

Characterization and comparison of immunologic phenotypes of both CSF and blood in participants with errors of immunity vs healthy controls, and longitudinally in participants using cellular and molecular immunologic techniques, including but not limited to immune cell phenotype, transcriptomics, metagenomics, and immune biomarkers.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2023-12-11
• Study First Submitted QC: 2023-12-12
• Study First Posted: 2023-12-13
• Study Start: 2024-01-12
• Status Verified: 2024-10-02
• Last Update Submitted: 2024-10-03
• Last Update Posted: 2024-10-04
• Primary Completion: 2043-01-01
• Study Completion: 2043-10-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Clinical characterization of neurologic manifestations in participants with recognized and unrecognized errors of immunity based on neurologic examination, neuroimaging, and other necessary neurologic tests depending on clinical presentation.	Through end of participation.	Clinically characterize neurologic manifestations of errors of immunity via neurologic exam and neuroimaging.
Characterization of inherited or acquired errors of immunity in participants with rare neurologic diseases.	Through end of participation.	Determine genetic defects in participants.

Secondary Outcome Measures

Name	Time	Method
Characterization and comparison of immunologic phenotypes of both CSF and blood in participants with errors of immunity vs healthy controls, and longitudinally in participants using cellular and molecular immunologic techniques.	Through end of participation.	Characterize immune cells in CSF and blood.

Trial Locations

Locations (1)

National Institutes of Health Clinical Center; 🇺🇸 Bethesda, Maryland, United States